Catalyst Biosciences


nassim usman spacer

Nassim Usman, Ph.D., Chief Executive Officer

Dr. Usman is currently CEO and a member of the Board of Directors at Catalyst Biosciences. Dr. Usman joined Catalyst from Morgenthaler Ventures, where he is a Venture Partner. Prior to joining Morgenthaler in 2005, he was Senior Vice President and Chief Operating Officer at Sirna Therapeutics Inc. (Nasdaq:RNAI – acquired by Merck NYSE:MRK) from 2004 to 2005 and held various R&D positions at both Sirna and Ribozyme Pharmaceuticals (Nasdaq:RZYM), including VP of R&D and Chief Scientific Officer, from 1992 to 2004. During his industrial career Dr. Usman has entered several drugs into clinical development, completed multiple licensing deals with pharmaceutical and biotechnology companies and raised capital in both private and public financings. Prior to moving into the biotechnology industry in 1992, Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and 130 patents and applications. Dr. Usman serves on the Boards of Mosaic Biosciences, Principia Biopharma and Osprey Pharmaceuticals, is a past director of Archemix Corporation (Cambridge, MA) and atugen AG (now Silence Therapeutics, LSE/AIM:SLN) and served on the SABs of RXi Pharmaceuticals and Noxxon Pharma AG. He received his B.Sc. (Honours) and Ph.D. in Organic Chemistry from McGill University. In his doctoral dissertation he developed a method for the solid-phase synthesis of RNA that is widely used in science and in a marketed RNA product (Macugen™).

edwin madison  

Edwin L. Madison, Ph.D., Chief Scientific Officer

Dr. Madison received a Ph.D. in biochemistry from University of Texas - Southwestern Medical Center (UTSWC) in 1990. Following graduation, Dr. Madison accepted a faculty position at UTSWC with joint appointments in the Departments of Biochemistry and Internal Medicine. Dr. Madison then moved to The Scripps Research Institute as an Associate Professor of Vascular Biology. Prior to moving to Catalyst Biosciences, Dr. Madison was Vice President of Biological Research at Dendreon San Diego and Dendreon Corporation, Professor of Vascular Biology at the Torrey Pines Institute for Molecular Studies, and Adjunct Professor of Vascular Biology at The Scripps Research Institute. Dr. Madison has achieved an international reputation in the fields of serine protease and serpin basic research, and he is one of the lead inventors of a currently marketed protease therapeutic agent.


Michael Keyoung, M.D., Ph.D., President, Catalyst Asia

Dr. Keyoung has more than 15 years of healthcare and life sciences experience through his role as physician, consultant, and investor. Dr. Keyoung joined Catalyst in 2013 from Burrill & Company, first round, Series A investor of Catalyst Biosciences. At Burrill & Company, Dr. Keyoung has served as Managing Director in Venture Capital and Private Equity and as Head of Burrill Pan-Asia. He has been involved in several successful private company investments such as Ferrokin Biosciences (acquired by Shire), oversaw public investments in the United States, Europe and Asia including Novadaq (NASDAQ:NVDQ) and Taiwan Liposome Company (GTSM:4152), and lead Pan-Asia transaction business. Previously, Dr. Keyoung was a co-founder of a life sciences healthcare investment partnership in New York. Dr. Keyoung also served as an advisor and consultant to leading life sciences venture capital firms, medical devices, pharma, and biotechnology companies. Dr. Keyoung was a Howard Hughes Medical Institute Research fellow and received his clinical surgical training at University of California, San Francisco and biomedical fellowship at Memorial Sloan Kettering Institute and Rockefeller University in New York. Dr. Keyoung performed preclinical drug discovery research for Aventis (now Sanofi-Aventis) and Merck while at Cornell and participated in translational clinical trials at leading academic centers. As a National Institute of Health-Medical Scientist Training Program scholarship recipient, Dr. Keyoung received both his Medical Doctorate and Ph.D. degrees in Neuroscience and Neurology from Cornell University Weill Medical College and Memorial Sloan Kettering Cancer Center. Dr. Keyoung has served on the Board of Directors at New York County Medical Society and Board of Overseers at Cornell University Weill Medical School and on the boards of private biopharma companies and organizations in the United States and in Asia.


Mike Smith, Chief Financial & Business Advisor

Mr. Smith has served as Catalyst Biosciences’ Chief Financial & Business Advisor since June 2012. He brings over 15 years experience in the biopharmaceutical industry in executive and management roles in Corporate Development, Strategy, Finance, Commercial and Project Management functions for companies ranging in size from 5,000 to 10 employees. Mr. Smith was most recently at iPierian as Vice President of Business Development. Prior to that, he served as CFO and Head of Business Development for Memory Pharmaceuticals (Nasdaq: MEMY), which was acquired by Roche in 2009, where he was responsible for overseeing all business development, finance, strategic planning, intellectual property and eventually site operation activities. Prior to Memory, Mr. Smith was Vice President of Business Development at QLT, Inc. (Nasdaq: QLTI). Mr. Smith entered the industry with Chiron (Nasdaq: CHIR) which was acquired by Novartis in 2006. Throughout his career, Mr. Smith has managed and led numerous hundred+ million dollar company acquisitions, product licensing transactions and strategic partnerships and financings. Mr. Smith holds a B.S. from the University of Virginia, as well as an MBA from the University of California, Berkeley.